[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"platelet-rich-plasma-injection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:platelet-rich-plasma-injection":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,75,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100630722","phase-4-pilot-exploration-of-platelet-characterization-of-platelet-rich-plasma-created-by-two-different-systems-100630722",false,"NCT07491367","Pilot Exploration of Platelet Characterization of Platelet Rich Plasma Created by Two Different Systems","PRP-PEPC","Inclusion Criteria:\n\n* Kellgren-Lawrence (KL) Grade 1-3 knee osteoarthritis\n* Symptoms of knee osteoarthritis for at least 3 months before presentation in one knee\n* Will be able to attend and perform physical therapy\n\nExclusion Criteria:\n\n* Received injection therapy for knee osteoarthritis in the past 6 months\n* Have severe arthritis diagnosed in ≥1 major joint by radiology criteria\n* History of septic arthritis\n* Underwent knee surgery for osteoarthritis or osteochondral defects within 1 year before randomization (e.g., autograft or allograft surgery)\n* Have had high tibial osteotomy, partial knee replacement, patellar resurfacing, total knee replacement, or have existing surgical hardware in the knee\n* Received a platelet-rich plasma injection elsewhere in the body within the past 3 months\n* Have a platelet disorder or bleeding disorder\n* Have a rheumatologic disease, autoimmune disorder, immunocompromised status, or active history of cancer\n* Are taking chemotherapy, require regular prednisone, or require regular anti-inflammatory use\n* Are pregnant, breastfeeding, or unwilling to practice birth control during the study\n* If both knees have osteoarthritis and the other knee has KL score equal to or greater than 2.\n* Have uncontrolled illness, physical disability, or other contraindication to aerobic exercise training","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The investigators would like to study the differences in the quality of Platelet Rich Plasma (PRP) between two different machines in those with knee osteoarthritis. Knee osteoarthritis means your cartilage has been worn down, and it affects your knee joint. Both machines, the APEX Biologix XCELL PRP System and the Emcyte PurePRP Supraphysiologic Concentrating System, are FDA approved, commercially available, and makes PRP. The investigators will check if the platelets in the PRP have different amounts or work differently. The investigators will also assess participants symptoms after the injection and compare the two different preparation systems.",[26,27,28,29],"Knee Osteoarthristis","Cartilage Damage","Platelet Rich Plasma","Platelet Rich Plasma Injection","NOT_YET_RECRUITING","2026-06-08",{"date":33,"type":34},"2026-06-09","ACTUAL",{"date":36,"type":20},"2026-07-01",{"date":38,"type":20},"2028-09",{"name":40,"class":41},"University of California, San Francisco","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100629327","comparison-of-platelet-rich-plasma-and-activated-cytokine-rich-serum-injection-treatments-in-patients-with-knee-osteoarthritis-koa-prp-acs-100629327","NCT07473232","Comparison of Platelet-rich Plasma and Activated Cytokine-rich Serum Injection Treatments in Patients With Knee Osteoarthritis. (KOA PRP ACS)","KOA PRP ACS","Inclusion Criteria:\n\n1. Diagnosis of knee osteoarthritis according to ACR criteria at least 6 months ago.\n2. Being between grade 1-2 according to the Kellgren-Lawrence radiological classification.\n3. Not having had PRP injection in the last year.\n4. Knee pain ≥ 5 according to the visual pain scale.\n\nExclusion Criteria:\n\n1. Those with significant neurological or cardiovascular disorders.\n2. Those with active thrombovascular disease.\n3. Those with joint or skin infections.\n4. Those who have recently had an infectious disease.\n5. Those infected with Hepatitis B, C, and HIV.\n6. Those who have received intra-articular knee injections (hyaluronic acid, PRP, corticosteroids, and others) within the last year.\n7. Those who use oral corticosteroids.\n8. Those who have used NSAIDs within the last week.\n9. Those who have used anti-platelet or anti-aggregant drugs within the last week.\n10. Those with coagulation disorders.\n11. Those with hemoglobin \\\u003C10 g\u002Fdl and platelet count \\\u003C100,000\n12. Those with cancer.\n13. Pregnant or breastfeeding women, drug addicts.\n14. Those scheduled for knee surgery or arthroscopy, or those who have undergone knee surgery or arthroscopy.\n15. Those with diseases causing secondary osteoarthritis:\n\n    1. post-traumatic,\n    2. congenital or developmental diseases\n\n       1. Local diseases (leg length discrepancy, varus, valgus deformities, hypermobility syndromes, scoliosis)\n       2. Generalized diseases (Bone dysplasias, Metabolic disorders (hemochromatosis, ochronosis, Gaucher disease, hemoglobinopathy, Ehlers-Danlos disease))\n    3. Calcium storage diseases (calcium pyrophosphate storage disease, etc.)\n    4. Other bone and joint diseases (avascular necrosis, rheumatoid arthritis, gouty arthritis, septic arthritis, Paget's disease, osteoporosis, osteochondritis)\n    5. Other diseases\n\n       1. Endocrine diseases (Diabetes mellitus, acromegaly, hypothyroidism, hyperthyroidism)\n       2. Neuropathic arthropathy (Charcot joint)\n       3. Other (Frost, Kashin-Beck disease, Caisson disease) -","40 Years","80 Years",{"count":53,"type":20},60,[55],"NA","The effects of single dose injection of platelet rich plasma or conditioned serum in the knee joint in patients with knee osteoarthritis will be compared",[58,29,59],"Knee Arthritis Osteoarthritis","Conditioned Serum",[61,62,63,64,65],"knee osteoarthritis","platelet rich plasma injection","conditioned serum injection","inflammation","cartilage","2026-03-16",{"date":68,"type":34},"2026-03-19",{"date":70,"type":20},"2026-04-01",{"date":72,"type":20},"2026-06-30",{"name":74,"class":41},"Pamukkale University",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":42},"100619016","the-effects-of-intra-articular-and-peri-articular-platelet-rich-plasma-prp-injections-n-chronic-knee-osteoarthritis-100619016","NCT07339137","The Effects of Intra-articular and Peri-articular Platelet-rich Plasma (PRP) Injections ın Chronic Knee Osteoarthritis","The Effects of Platelet-rich Plasma (PRP) Injections Administered Into Intra-articular and Periarticular Regions Under Ultrasound Guidance in Chronic Knee Osteoarthritis on Pain, Function, Activities of Daily Living, Medial Collateral Ligament (MCL) and Distal Femoral Cartilage Thickness","Inclusion Criteria\n\n* Age between 40 and 65 years.\n* Patients with significant medial knee pain who have not responded to conservative treatment for at least 3 months.\n* Patients diagnosed with knee osteoarthritis according to the American College of Rheumatology (ACR) criteria and with Kellgren-Lawrence grade 2 or 3 radiographic osteoarthritis.\n* Intact cognitive function.\n* Willingness to participate in the study and provide signed informed consent.\n* Visual Analog Scale (VAS) score of 4 or higher.\n\nExclusion Criteria\n\n* History of previous knee trauma or surgery.\n* Physical therapy, intra-articular steroid, or hyaluronic acid injections in the knee within the last 3 months.\n* Active oncological diseases.\n* Local infection, sepsis, wounds, or scars in the injection area.\n* Systemic infections, hepatitis, or immunosuppression.\n* Bleeding diathesis or irregular International Normalized Ratio (INR) due to oral warfarin use.\n* Inflammatory arthropathies.\n* Uncontrolled hypertension, uncontrolled diabetes mellitus, decompensated heart failure, coronary artery disease, or asthma.\n* Suspected or confirmed pregnancy.\n* Use of corticosteroids or opioids.\n* Anemia.\n* Body mass index (BMI) greater than 35.\n* Allergy to citrate.\n* Use of nonsteroidal anti-inflammatory drugs (NSAIDs) within the last week that may affect platelet function analyzer-100 (PFA-100) activity.\n* Physical examination findings suggestive of patellar retinaculum, meniscus, or cruciate ligament injury.\n* General health impairment or lack of cooperation.\n* Refusal to participate in the study.","65 Years",{"count":84,"type":20},42,[55],"The primary objective of this study is to evaluate and compare the effectiveness of ultrasound-guided combined intra-articular and peri-articular platelet-rich plasma (PRP) injections with intra-articular PRP injections alone in patients with chronic knee osteoarthritis (OA). The study specifically examines the effects of these treatment approaches on pain, physical function, activities of daily living, and structural parameters, including medial collateral ligament (MCL) thickness and distal femoral cartilage thickness.\n\nOsteoarthritis is a degenerative joint disease characterized by progressive cartilage erosion, osteophyte formation, and subchondral sclerosis, leading to pain, stiffness, and functional disability. It is the most common form of arthritis and a leading cause of disability worldwide, affecting approximately 300 million individuals. Although the knee is the most frequently involved joint, OA is now recognized as a whole-joint disease, involving not only cartilage degeneration but also pathological changes in subchondral bone, synovium, and surrounding extra-articular structures.\n\nPlatelet-rich plasma is an autologous concentration of platelets suspended in a small volume of plasma and contains a variety of bioactive growth factors, such as transforming growth factor-beta (TGF-β), platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF). These factors play a crucial role in promoting cell proliferation, angiogenesis, and tissue repair. In knee OA, PRP has been shown to reduce matrix metalloproteinase (MMP) activity, particularly MMP-13, enhance endogenous hyaluronic acid production, and support chondrogenesis. Although intra-articular PRP injections are widely accepted as a safe and effective treatment and have demonstrated superiority over placebo and hyaluronic acid in long-term follow-up studies, most existing research has focused exclusively on intra-articular applications.\n\nKnee OA is a multifactorial condition frequently associated with extra-articular pathologies, including ligament laxity, peri-articular edema, and soft tissue inflammation. Limiting treatment to the intra-articular space alone may therefore overlook these important contributors to pain and functional impairment. Emerging evidence suggests that a combined treatment approach targeting both intra-articular and peri-articular structures may provide superior outcomes in terms of pain reduction and functional improvement.\n\nThis prospective randomized controlled trial will include 42 patients aged 40-65 years with chronic knee OA classified as Kellgren-Lawrence grade 2 or 3. Participants will be randomly assigned to one of three groups: a control group receiving conservative treatment only (exercise therapy and lifestyle modifications), a group receiving conservative treatment plus ultrasound-guided intra-articular PRP injections, and a third group receiving conservative treatment plus combined ultrasound-guided intra-articular and peri-articular PRP injections targeting the MCL and pes anserinus regions.\n\nClinical outcomes will be assessed using validated instruments, including the Visual Analog Scale (VAS), the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and the Short Form-36 (SF-36) Quality of Life Scale. In addition, ultrasonographic measurements of MCL thickness and distal femoral cartilage thickness will be performed to evaluate structural changes. By investigating the additional value of peri-articular PRP injections, this study aims to contribute to the development of more comprehensive and effective injection protocols for the management of chronic knee osteoarthritis.",[29,88,89],"Ultrasonography","Gonarthrosis",[61,91,92,93,94,95],"periarticular","PRP","USG","Femoral Cartilage","Medial Collateral Ligament","RECRUITING","2026-01-13",{"date":99,"type":34},"2026-01-15",{"date":101,"type":34},"2025-08-01",{"date":103,"type":20},"2026-04-30",{"name":105,"class":41},"Ankara City Hospital Bilkent",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":113,"minAge":114,"maxAge":82,"enrollmentInfo":115,"targetDuration":4,"studyType":21,"phases":117,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":42},"100604509","the-effects-of-platelet-rich-plasma-adjuvant-to-type-iiii-collagen-ratio-matrix-metalloproteinase-2-and-matrix-metalloproteinase-9-in-pelvic-organ-prolapse-repair-100604509","NCT07150442","The Effects of Platelet Rich Plasma Adjuvant to Type I\u002FIII Collagen Ratio, Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9 in Pelvic Organ Prolapse Repair","POP PRP MMP","Inclusion Criteria:\n\n1. Patients with second-degree or higher pelvic organ prolapse\n2. Postmenopausal pelvic organ prolapse patients\n3. Patients with pelvic organ prolapse who will undergo surgery\n4. Willingness to participate in the study\n\nExclusion Criteria:\n\n1. Patients with gynecological malignancies\n2. Patients with a history of collagen disease\n3. Patients with blood disorders","FEMALE","45 Years",{"count":116,"type":20},30,[55],"The goal of this clinical trial is to analyze the effect of Platelet Rich Plasma (PRP) Adjuvant To Type I\u002FIII Colagen Ratio, MMP-2 and MMP-9 in Pelvic Organ Prolapse Repair.\n\nThe main questions it aims to answer are:\n\nDoes the PRP Adjuvant affect type I\u002FIII Colagen Ratio, MMP-2 and MMP-9 in Pelvic Organ Prolapse Repair? Researchers will compare patient who undergo prolapse surgery with PRP adjuvant versus patient who undergo prolapse surgery without PRP adjuvant (placeebo)\n\nParticipants will:\n\nPatient will undergo pelvic organ prolapse reconstrucion surgery and punch biopsy and injection of PRP will perform in anterior vaginal mucosa at Pubocervical area. The second biopsy will attempt in 8 weeks post operative. imunohistochemistry examination will be done to compare the type I\u002FIII Colagen Ratio, MMP-2 and MMP-9 before and after surgery.",[120,29],"Pelvic Organ Prolapse Vaginal Surgery",[122,123,124,125,126,127],"Pelvic organ prolapse surgery","Platelet rich plasma injection","Type I\u002FIII collagen ratio","MMP-2","MMP-9","Randomized controlled trial","2025-09-02",{"date":130,"type":34},"2025-09-08",{"date":132,"type":34},"2025-08-27",{"date":134,"type":20},"2026-08",{"name":136,"class":41},"Andalas University"]